Insinga Alessandra, Monestiroli Silvia, Ronzoni Simona, Carbone Roberta, Pearson Mark, Pruneri Giancarlo, Viale Giuseppe, Appella Ettore, Pelicci PierGiuseppe, Minucci Saverio
Department of Experimental Oncology, European Institute of Oncology, Milan, Italy.
EMBO J. 2004 Mar 10;23(5):1144-54. doi: 10.1038/sj.emboj.7600109. Epub 2004 Feb 19.
Mutations of p53 are remarkably rare in acute promyelocytic leukemias (APLs). Here, we demonstrate that the APL-associated fusion proteins PML-RAR and PLZF-RAR directly inhibit p53, allowing leukemic blasts to evade p53-dependent cancer surveillance pathways. PML-RAR causes deacetylation and degradation of p53, resulting in repression of p53 transcriptional activity, and protection from p53-dependent responses to genotoxic stress. These phenomena are dependent on the expression of wild-type PML, acting as a bridge between p53 and PML-RAR. Recruitment of histone deacetylase (HDAC) to p53 and inhibition of p53 activity were abrogated by conditions that either inactivate HDACs or trigger HDAC release from the fusion protein, implicating recruitment of HDAC by PML-RAR as the mechanism underlying p53 inhibition.
在急性早幼粒细胞白血病(APL)中,p53的突变极为罕见。在此,我们证明APL相关的融合蛋白PML-RAR和PLZF-RAR直接抑制p53,使白血病原始细胞逃避p53依赖性癌症监测途径。PML-RAR导致p53的去乙酰化和降解,从而抑制p53的转录活性,并保护细胞免受p53依赖性基因毒性应激反应的影响。这些现象依赖于野生型PML的表达,它作为p53与PML-RAR之间的桥梁发挥作用。使组蛋白脱乙酰酶(HDAC)失活或触发HDAC从融合蛋白释放的条件,可消除HDAC向p53的募集并抑制p53活性,这表明PML-RAR募集HDAC是p53抑制的潜在机制。